PCR Technologies Market - Global Forecast To 2030
商品番号 : SMB-24411
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年10月 |
| ページ数 | 305 |
| 図表数 | 305 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The PCR technologies market is projected to reach USD 21.89 Billion by 2030 from USD 14.61 in 2024, growing at a CAGR of 7.0% during the forecast period.
PCR技術市場は、2024年の14.61米ドルから2030年までに218億9,000万米ドルに達すると予測されており、予測期間中に7.0%のCAGRで成長します。
The market is growing due to numerous factors.Increasing cases of infectious diseases, and regular advancements in PCR technologies drives this market. Rising expenditure in research and development and increase in application of biomarker profiling to detect diseases are other factors. Additionally, the market growth is affected by inclusion of PCR technology with artificial intelligence.
“qPCR to account for largest market share in 2023.”
A variant of the Polymerase Chain Reaction (PCR) called quantitative PCR (qPCR), sometimes referred to as real-time PCR, enables the simultaneous amplification and quantification of a particular DNA or RNA sequence. qPCR tracks the reaction in real time as it develops and provides quantitative information on the amount of target nucleic acid, in contrast to traditional PCR, which only identifies the presence of genetic material after the reaction is finished. The market is driven by the rising demand for qPCR instruments, the increasing prevalence of illnesses, and technical advances. Moreover, qPCR is a very specific and sensitive method for identifying and measuring nucleic acids, which makes it necessary for the diagnosis of infectious disorders.
“Diagnostic Laboratories to hold largest share in the market.”
Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decrease cost, expedites testing methods, and improve precision and accuracy of diagnosis. Diagnostic labs require PCR identify and diagnose a variety of illnesses. These labs use PCR extensively because of its precision, sensitivity, and speed in diagnosing genetic abnormalities, and infectious diseases.
“North America to register largest share in 2023.”
The largest share was hold by North America in 2023. North America comprise US and Canada.
The growth is supported by increase in drug development associated with genomics. Apart from that, government led initiatives and increase in funding and grants supports growth. The region also has strong presence of prominent players who support the growth of this market by carrying out strategic partnerships, collaborations, expansion and acquisitions. Wide application of PCR methods in hospitals and diagnostic labs of this region is also increasing the demand for microfluidics in North America.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3– 20%
- By Designation: C-level– 35%, Director-level–25%, and Others–40%
- By Region: North America–40%, Europe-30%, Asia Pacific–20%, Latin America- 5%, Middle East and Africa- 5%
Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Sansure Biotech Inc. (China) Becton, Dickinson and Company (US) and Analytik Jena AG (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Illumina, Inc. (US), Bioneer Corporation (South Korea), PerkinElmer Inc. (US), Hologic Inc. (US),.
Research Coverage
The report comprise segmentation that includes end users, products, applications, and geographic regions. It also discusses the key drivers, restraints, opportunities, and challenges affecting the growth of the PCR technologies market. The research offers stakeholders an assessment of market potential and challenges, with a focus on key players and competitive landscapes. Additionally, micromarkets are assessed according to their overall to the microfluidics sector, growth patterns, and potential. The analysis estimates increase in market segment revenues, focusing on five regions.
Key Benefits of Buying the Report:
This research aids new and existing players in the PCR technologies market to assess the sustainability of their investments by offering detailed information. It offers a dataset to assist in making key decisions. The main advantage of this report includes risk evaluation and offering direction for investment decisions. Market segmentation as per the end-users and geographical areas is offered in the study, that provides analysis and insights. It also provides trends, obstacles, opportunities, and drivers, giving stakeholders the information they need to make strategic decisions.
The report provides the insights on the following pointers:
Analysis of the key drivers, restraints, opportunities, and challenges impacting the PCR technologies market growth: advanced technology and rise in prevalence of infectious diseases ; premium price of devices and strict regulations ; rise in number of diagnostic centers/labs.
- Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.
- Market Development: Details related to profitable markets: this research discussees the PCR technologies business in numerous regions.
- Market Diversification: Detailed understanding of advanced products, unexplored areas, latest developments, and investment in the market.
- Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Agilent Technologies, Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).
Table of Contents
1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
1.3 STUDY SCOPE 28
1.3.1 SEGMENTS CONSIDERED 28
1.3.2 INCLUSIONS & EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 29
1.3.4 CURRENCY CONSIDERED 29
1.4 STAKEHOLDERS 29
1.5 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.2 RESEARCH DESIGN 32
2.2.1 SECONDARY RESEARCH 32
2.2.1.1 Key secondary sources 32
2.2.1.2 Key objectives of secondary research 33
2.2.1.3 Key data from secondary sources 34
2.2.2 PRIMARY RESEARCH 34
2.2.2.1 Key primary sources 35
2.2.2.2 Key objectives of primary research 35
2.2.2.3 Key industry insights 36
2.2.2.4 Breakdown of primaries 36
2.3 MARKET SIZE ESTIMATION 37
2.3.1 BOTTOM-UP APPROACH 38
2.3.1.1 Company revenue estimation approach 38
2.3.1.2 Customer-based market estimation 39
2.3.1.3 Top-down approach 40
2.3.1.4 Primary interviews 41
2.3.2 GROWTH FORECAST 41
2.4 DATA TRIANGULATION 42
2.5 MARKET SHARE ASSESSMENT 43
2.6 STUDY ASSUMPTIONS 43
2.7 GROWTH ASSUMPTIONS 43
2.8 RISK ASSESSMENT 45
2.9 RESEARCH LIMITATIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 PCR TECHNOLOGIES MARKET OVERVIEW 51
4.2 PCR TECHNOLOGIES MARKET, BY REGION, 2024 VS. 2030 (USD MILLION) 52
4.3 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY AND END USER,
2023 (USD MILLION) 53
4.4 PCR TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 55
5.2.1.1 Increasing outbreaks of infectious diseases/viral persistence 55
5.2.1.2 Development of miniaturized and portable point-of-care testing devices 56
5.2.1.3 Integration of PCR technology with automation and data analysis tools 57
5.2.1.4 High demand for technologically advanced molecular diagnostics 58
5.2.2 RESTRAINTS 59
5.2.2.1 Premium product pricing 59
5.2.2.2 Dearth of skilled healthcare professionals 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 Increased investments in laboratory infrastructure 61
5.2.3.2 Rising number of applications in rare sequence detection 61
5.2.4 CHALLENGES 62
5.2.4.1 Technical limitations 62
5.2.4.2 Increased pricing pressure on market players 62
5.3 VALUE CHAIN ANALYSIS 63
5.3.1 RESEARCH & DEVELOPMENT 63
5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 63
5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES 63
5.4 PORTER’S FIVE FORCES ANALYSIS 65
5.4.1 THREAT OF NEW ENTRANTS 66
5.4.2 THREAT OF SUBSTITUTES 66
5.4.3 BARGAINING POWER OF SUPPLIERS 66
5.4.4 BARGAINING POWER OF BUYERS 66
5.4.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.5 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS 67
5.5.2 KEY BUYING CRITERIA 67
5.6 PATENT ANALYSIS 68
5.6.1 LIST OF MAJOR PATENTS 69
5.7 KEY CONFERENCES AND EVENTS, 2024–2025 70
5.8 TRADE DATA ANALYSIS 71
5.8.1 IMPORT DATA FOR HS CODE 3822 71
5.8.2 EXPORT DATA FOR HS CODE 3822 72
5.9 PRICING ANALYSIS 72
5.9.1 PRICE TRENDS OF PCR TECHNOLOGIES, BY REGION 72
5.9.2 INDICATIVE SELLING PRICE OF PCR TECHNOLOGY PRODUCTS, BY REGION, 2021–2023 74
5.9.3 AVERAGE SELLING PRICE TREND, BY REGION 75
5.9.3.1 Average selling price trend of PCR technology equipment, by region 75
5.9.3.2 Average selling price trend of PCR instruments, by key player 76
5.10 UNMET NEEDS AND KEY PAIN POINTS 77
5.11 ECOSYSTEM ANALYSIS 77
5.12 SUPPLY CHAIN ANALYSIS 79
5.12.1 MANUFACTURING COMPANIES 79
5.12.2 SALES & DISTRIBUTION AGENTS 79
5.12.3 END USERS 79
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
5.14 TECHNOLOGY ANALYSIS 81
5.14.1 KEY TECHNOLOGIES 81
5.14.1.1 Thermal cyclers 81
5.14.1.2 Real-time quantitative PCR 81
5.14.1.3 Portable and point-of-care PCR 81
5.14.2 COMPLEMENTARY TECHNOLOGIES 82
5.14.2.1 Next-generation sequencing 82
5.14.2.2 Microarrays 82
5.14.2.3 Lab-on-a-chip devices 82
5.14.2.4 Robotics and automation 82
5.14.3 ADJACENT TECHNOLOGIES 83
5.14.3.1 Mass spectrometry 83
5.14.3.2 Single-cell sequencing 83
5.14.3.3 Fluorescence in situ hybridization 83
5.15 REGULATORY LANDSCAPE 83
5.15.1 REGULATORY ANALYSIS 84
5.15.1.1 North America 84
5.15.1.1.1 US 84
5.15.1.1.2 Canada 84
5.15.1.2 Europe 85
5.15.1.3 Asia Pacific 85
5.15.1.3.1 Japan 85
5.15.1.3.2 China 86
5.15.1.3.3 India 87
5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
5.16 INVESTMENT AND FUNDING SCENARIO 89
5.17 REIMBURSEMENT SCENARIO ANALYSIS 90
5.18 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET 92
6 PCR TECHNOLOGIES MARKET, BY PRODUCT 94
6.1 INTRODUCTION 95
6.2 REAGENTS AND CONSUMABLES 95
6.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET 95
6.3 INSTRUMENTS 96
6.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH 96
6.4 SOFTWARE AND SERVICES 98
6.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE FOR ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH 98
7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE 99
7.1 INTRODUCTION 100
7.2 REAL-TIME PCR 100
7.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH 100
7.3 CONVENTIONAL PCR 103
7.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH 103
7.4 DIGITAL PCR 106
7.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION 106
7.5 REVERSE TRANSCRIPTION PCR 108
7.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH 108
7.6 HOT-START PCR 111
7.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH 111
7.7 MULTIPLEX PCR 114
7.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH 114
7.8 OTHER PCR TECHNIQUES 117
8 PCR TECHNOLOGIES MARKET, BY APPLICATION 120
8.1 INTRODUCTION 121
8.2 DIAGNOSTIC APPLICATIONS 122
8.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH 122
8.3 GENOTYPING 123
8.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH 123
8.4 NUCLEIC ACID DETECTION 124
8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH 124
8.5 GENE EXPRESSION ANALYSIS 125
8.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH 125
8.6 NUCLEIC ACID SYNTHESIS 126
8.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH 126
8.7 GENETIC SEQUENCING 127
8.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH 127
8.8 ENVIRONMENTAL APPLICATIONS 128
8.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR 128
8.9 STANDARD VALIDATION/VERIFICATION 129
8.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET 129
8.10 OTHER APPLICATIONS 129
9 PCR TECHNOLOGIES MARKET, BY END USER 131
9.1 INTRODUCTION 132
9.2 HOSPITAL LABORATORIES 132
9.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH 132
9.3 DIAGNOSTIC LABORATORIES 133
9.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH 133
9.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS 134
9.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET 134
9.5 PHARMA-BIOTECH COMPANIES 135
9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES 135
9.6 OTHER END USERS 136
10 PCR TECHNOLOGIES MARKET, BY REGION 138
10.1 INTRODUCTION 139
10.2 NORTH AMERICA 139
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 140
10.2.2 US 145
10.2.2.1 US to dominate North American PCR technologies market during study period 145
10.2.3 CANADA 147
10.2.3.1 Supportive government initiatives for genomics research to aid market growth 147
10.3 EUROPE 149
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 149
10.3.2 GERMANY 153
10.3.2.1 Presence of well-established pharmaceutical and R&D industry to augment market growth 153
10.3.3 FRANCE 155
10.3.3.1 Increasing investments in life science R&D for infrastructural development to favor market growth 155
10.3.4 UK 157
10.3.4.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth 157
10.3.5 ITALY 159
10.3.5.1 Supportive government policies and high healthcare expenditure to boost market growth 159
10.3.6 SPAIN 161
10.3.6.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth 161
10.3.7 REST OF EUROPE 162
10.4 ASIA PACIFIC 164
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 164
10.4.2 CHINA 169
10.4.2.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth 169
10.4.3 JAPAN 170
10.4.3.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth 170
10.4.4 INDIA 172
10.4.4.1 Presence of large target patient population and high government healthcare expenditure to support market growth 172
10.4.5 AUSTRALIA 174
10.4.5.1 High healthcare expenditure to drive adoption of advanced PCR technologies 174
10.4.6 SOUTH KOREA 176
10.4.6.1 Improved medical tourism and prevalence of chronic diseases to propel market growth 176
10.4.7 REST OF ASIA PACIFIC 178
10.5 LATIN AMERICA 179
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 179
10.5.2 BRAZIL 183
10.5.2.1 Growing focus on proteomics and genomics research to drive market 183
10.5.3 MEXICO 185
10.5.3.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments 185
10.5.4 REST OF LATIN AMERICA 187
10.6 MIDDLE EAST & AFRICA 188
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 189
10.6.2 GCC COUNTRIES 192
10.6.2.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth 192
10.6.3 REST OF MIDDLE EAST & AFRICA 193
11 COMPETITIVE LANDSCAPE 195
11.1 INTRODUCTION 195
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 195
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET 195
11.3 REVENUE ANALYSIS, 2019–2023 197
11.4 MARKET SHARE ANALYSIS, 2023 197
11.4.1 GLOBAL PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2023 197
11.4.2 GLOBAL PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2023 198
11.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2023 199
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 201
11.5.1 STARS 201
11.5.2 EMERGING LEADERS 201
11.5.3 PERVASIVE PLAYERS 201
11.5.4 PARTICIPANTS 202
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 203
11.5.5.1 Company footprint 203
11.5.5.2 Product footprint 204
11.5.5.3 Application footprint 204
11.5.5.4 Technique footprint 205
11.5.5.5 End-user footprint 206
11.5.5.6 Region footprint 207
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 207
11.6.1 PROGRESSIVE COMPANIES 207
11.6.2 RESPONSIVE COMPANIES 208
11.6.3 DYNAMIC COMPANIES 208
11.6.4 STARTING BLOCKS 208
11.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2023 209
11.7 COMPANY VALUATION AND FINANCIAL METRICS 210
11.8 PRODUCT/BRAND COMPARISON 212
11.9 COMPETITIVE SCENARIO 212
11.9.1 PRODUCT LAUNCHES AND APPROVALS 213
11.9.2 DEALS 213
12 COMPANY PROFILES 215
12.1 KEY PLAYERS 215
12.1.1 THERMO FISHER SCIENTIFIC INC. 215
12.1.1.1 Business overview 215
12.1.1.2 Products/Services/Solutions offered 216
12.1.1.3 Recent developments 218
12.1.1.3.1 Product launches and approvals 218
12.1.1.3.2 Deals 219
12.1.1.4 MnM view 220
12.1.1.4.1 Key strengths 220
12.1.1.4.2 Strategic choices 220
12.1.1.4.3 Weaknesses and competitive threats 220
12.1.2 F. HOFFMANN-LA ROCHE LTD. 221
12.1.2.1 Business overview 221
12.1.2.2 Products/Services/Solutions offered 222
12.1.2.3 Recent developments 224
12.1.2.3.1 Product launches and approvals 224
12.1.2.3.2 Deals 225
12.1.2.4 MnM view 225
12.1.2.4.1 Key strengths 225
12.1.2.4.2 Strategic choices 225
12.1.2.4.3 Weaknesses and competitive threats 225
12.1.3 AGILENT TECHNOLOGIES, INC. 226
12.1.3.1 Business overview 226
12.1.3.2 Products/Services/Solutions offered 227
12.1.3.3 Recent developments 230
12.1.3.3.1 Product launches 230
12.1.3.3.2 Deals 230
12.1.3.4 MnM view 230
12.1.3.4.1 Key strengths 230
12.1.3.4.2 Strategic choices 230
12.1.3.4.3 Weaknesses and competitive threats 231
12.1.4 BIO-RAD LABORATORIES, INC. 232
12.1.4.1 Business overview 232
12.1.4.2 Products/Services/Solutions offered 233
12.1.4.3 Recent developments 236
12.1.4.3.1 Product launches 236
12.1.4.3.2 Deals 236
12.1.4.4 MnM view 237
12.1.4.4.1 Key strengths 237
12.1.4.4.2 Strategic choices 237
12.1.4.4.3 Weaknesses and competitive threats 237
12.1.5 QIAGEN 238
12.1.5.1 Business overview 238
12.1.5.2 Products/Services/Solutions offered 239
12.1.5.3 Recent developments 241
12.1.5.3.1 Product launches and approvals 241
12.1.5.3.2 Deals 242
12.1.5.4 MnM view 243
12.1.5.4.1 Key strengths 243
12.1.5.4.2 Strategic choices 243
12.1.5.4.3 Weaknesses and competitive threats 243
12.1.6 DANAHER CORPORATION 244
12.1.6.1 Business overview 244
12.1.6.2 Products/Services/Solutions offered 245
12.1.6.3 Recent developments 247
12.1.6.3.1 Product approvals 247
12.1.6.3.2 Deals 247
12.1.7 ABBOTT 248
12.1.7.1 Business overview 248
12.1.7.2 Products/Services/Solutions offered 249
12.1.7.3 Recent developments 250
12.1.7.3.1 Product approvals 250
12.1.8 TAKARA BIO INC. 251
12.1.8.1 Business overview 251
12.1.8.2 Products/Services/Solutions offered 252
12.1.8.3 Recent developments 254
12.1.8.3.1 Deals 254
12.1.9 ANALYTIK JENA GMBH+CO. KG 255
12.1.9.1 Business overview 255
12.1.9.2 Products/Services/Solutions offered 255
12.1.9.3 Recent developments 256
12.1.9.3.1 Product launches 256
12.1.9.3.2 Deals 257
12.1.10 MERCK KGAA 258
12.1.10.1 Business overview 258
12.1.10.2 Products/Services/Solutions offered 259
12.1.11 BIONEER CORPORATION 263
12.1.11.1 Business overview 263
12.1.11.2 Products/Services/Solutions offered 264
12.1.12 PERKINELMER 266
12.1.12.1 Business overview 266
12.1.12.2 Products/Services/Solutions offered 267
12.1.12.3 Recent developments 268
12.1.12.3.1 Other developments 268
12.1.13 BECTON, DICKINSON AND COMPANY 269
12.1.13.1 Business overview 269
12.1.13.2 Products/Services/Solutions offered 270
12.1.13.3 Recent developments 271
12.1.13.3.1 Product launches and approvals 271
12.1.13.3.2 Deals 272
12.1.14 STANDARD BIOTOOLS 273
12.1.14.1 Business overview 273
12.1.14.2 Products/Services/Solutions offered 274
12.1.15 HOLOGIC, INC. 276
12.1.15.1 Business overview 276
12.1.15.2 Products/Services/Solutions offered 277
12.1.15.3 Recent developments 278
12.1.15.3.1 Product launches 278
12.1.16 LONZA 279
12.1.16.1 Business overview 279
12.1.16.2 Products/Services/Solutions offered 280
12.1.17 ILLUMINA, INC. 281
12.1.17.1 Business overview 281
12.1.17.2 Products/Services/Solutions offered 282
12.1.18 SANSURE BIOTECH INC. 283
12.1.18.1 Business overview 283
12.1.18.2 Products/Services/Solutions offered 284
12.2 OTHER PLAYERS 285
12.2.1 PROMEGA CORPORATION 285
12.2.2 LIMING BIO 286
12.2.3 EPPENDORF SE 287
12.2.4 TRANSGEN BIOTECH CO., LTD. 288
12.2.5 DAAN GENE CO., LTD. 289
12.2.6 BIOBASE GROUP 290
12.2.7 NIPPON GENETICS EUROPE 291
12.2.8 BIOMÉRIEUX 292
12.2.9 DAIICHI SANKYO COMPANY, LIMITED 293
12.2.10 STILLA 294
12.2.11 GENSCRIPT 295
13 APPENDIX 296
13.1 DISCUSSION GUIDE 296
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 301
13.3 CUSTOMIZATION OPTIONS 303
13.4 RELATED REPORTS 303
13.5 AUTHOR DETAILS 304
LIST OF TABLES
TABLE 1 PCR TECHNOLOGIES MARKET: STUDY ASSUMPTIONS 43
TABLE 2 PCR TECHNOLOGIES MARKET: RISK ASSESSMENT 45
TABLE 3 NUMBER OF REPORTED CASES OF INFECTIOUS DISEASES,
JANUARY 2019–DECEMBER 2022 56
TABLE 4 ADVANTAGES AND DISADVANTAGES OF REAL-TIME POINT-OF-CARE RT-PCR DEVICES 57
TABLE 5 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES 65
TABLE 6 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 67
TABLE 7 PCR TECHNOLOGIES MARKET: LIST OF MAJOR PATENTS,
JANUARY 2022–DECEMBER 2024 69
TABLE 8 PCR TECHNOLOGIES MARKET: LIST OF KEY CONFERENCES AND EVENTS,
JANUARY 2024–DECEMBER 2025 70
TABLE 9 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019–2023 (USD THOUSAND) 71
TABLE 10 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019−2023 (USD THOUSAND) 72
TABLE 11 INDICATIVE SELLING PRICE OF PCR TECHNOLOGY PRODUCTS, BY REGION,
2021–2023 (USD) 74
TABLE 12 AVERAGE SELLING PRICE OF PCR INSTRUMENTS, BY KEY PLAYER, 2023 (USD) 76
TABLE 13 PCR TECHNOLOGIES MARKET: CURRENT UNMET NEEDS 77
TABLE 14 PCR TECHNOLOGIES MARKET: ROLE IN ECOSYSTEM 78
TABLE 15 US: CLASSIFICATION OF PCR TECHNOLOGY-ASSOCIATED DIAGNOSTIC DEVICES 84
TABLE 16 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 84
TABLE 17 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
TABLE 18 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 86
TABLE 19 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 86
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88
TABLE 24 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89
TABLE 25 REIMBURSEMENT CODES FOR PCR TESTING, 2023 91
TABLE 26 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 95
TABLE 27 PCR TECHNOLOGIES MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2022–2030 (USD MILLION) 96
TABLE 28 PCR TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION,
2022–2030 (USD MILLION) 97
TABLE 29 PCR TECHNOLOGIES MARKET FOR SOFTWARE AND SERVICES, BY REGION,
2022–2030 (USD MILLION) 98
TABLE 30 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022–2030 (USD MILLION) 100
TABLE 31 REAL-TIME PCR MARKET, BY REGION, 2022–2030 (USD MILLION) 101
TABLE 32 REAL-TIME PCR MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 102
TABLE 33 REAL-TIME PCR MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 102
TABLE 34 REAL-TIME PCR MARKET, BY END USER, 2022–2030 (USD MILLION) 103
TABLE 35 CONVENTIONAL PCR MARKET, BY REGION, 2022–2030 (USD MILLION) 104
TABLE 36 CONVENTIONAL PCR MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 104
TABLE 37 CONVENTIONAL PCR MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 105
TABLE 38 CONVENTIONAL PCR MARKET, BY END USER, 2022–2030 (USD MILLION) 105
TABLE 39 DIGITAL PCR MARKET, BY REGION, 2022–2030 (USD MILLION) 106
TABLE 40 DIGITAL PCR MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 107
TABLE 41 DIGITAL PCR MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 107
TABLE 42 DIGITAL PCR MARKET, BY END USER, 2022–2030 (USD MILLION) 108
TABLE 43 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR 109
TABLE 44 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2022–2030 (USD MILLION) 109
TABLE 45 REVERSE TRANSCRIPTION PCR MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 110
TABLE 46 REVERSE TRANSCRIPTION PCR MARKET, BY APPLICATION,
2022–2030 (USD MILLION) 110
TABLE 47 REVERSE TRANSCRIPTION PCR MARKET, BY END USER,
2022–2030 (USD MILLION) 111
TABLE 48 BENEFITS AND CONSIDERATIONS OF HOT-START PCR TECHNOLOGY 112
TABLE 49 HOT-START PCR MARKET, BY REGION, 2022–2030 (USD MILLION) 112
TABLE 50 HOT-START PCR MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 113
TABLE 51 HOT-START PCR MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 113
TABLE 52 HOT-START PCR MARKET, BY END USER, 2022–2030 (USD MILLION) 114
TABLE 53 MULTIPLEX PCR MARKET, BY REGION, 2022–2030 (USD MILLION) 115
TABLE 54 MULTIPLEX PCR MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 115
TABLE 55 MULTIPLEX PCR MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 116
TABLE 56 MULTIPLEX PCR MARKET, BY END USER, 2022–2030 (USD MILLION) 116
TABLE 57 OTHER PCR TECHNIQUES MARKET, BY REGION, 2022–2030 (USD MILLION) 117
TABLE 58 OTHER PCR TECHNIQUES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 118
TABLE 59 OTHER PCR TECHNIQUES MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 118
TABLE 60 OTHER PCR TECHNIQUES MARKET, BY END USER, 2022–2030 (USD MILLION) 119
TABLE 61 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 121
TABLE 62 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022–2030 (USD MILLION) 122
TABLE 63 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION,
2022–2030 (USD MILLION) 123
TABLE 64 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION,
2022–2030 (USD MILLION) 124
TABLE 65 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2022–2030 (USD MILLION) 125
TABLE 66 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION,
2022–2030 (USD MILLION) 126
TABLE 67 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION,
2022–2030 (USD MILLION) 127
TABLE 68 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2022–2030 (USD MILLION) 128
TABLE 69 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION,
BY REGION, 2022–2030 (USD MILLION) 129
TABLE 70 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION,
2022–2030 (USD MILLION) 130
TABLE 71 PCR TECHNOLOGIES MARKET, BY END USER, 2022–2030 (USD MILLION) 132
TABLE 72 PCR TECHNOLOGIES MARKET FOR HOSPITAL LABORATORIES, BY REGION,
2022–2030 (USD MILLION) 133
TABLE 73 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2030 (USD MILLION) 134
TABLE 74 PCR TECHNOLOGIES MARKET FOR ACADEMIC AND GOVERNMENT ORGANIZATIONS, BY REGION, 2022–2030 (USD MILLION) 135
TABLE 75 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2022–2030 (USD MILLION) 136
TABLE 76 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION,
2022–2030 (USD MILLION) 137
TABLE 77 PCR TECHNOLOGIES MARKET, BY REGION, 2022–2030 (USD MILLION) 139
TABLE 78 NORTH AMERICA: KEY MACROINDICATORS 140
TABLE 79 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 142
TABLE 80 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 142
TABLE 81 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 143
TABLE 82 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022–2030 (USD MILLION) 144
TABLE 83 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER,
2022–2030 (USD MILLION) 145
TABLE 84 US: KEY MACROINDICATORS 146
TABLE 85 US: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 146
TABLE 86 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022–2030 (USD MILLION) 147
TABLE 87 CANADA: KEY MACROINDICATORS 147
TABLE 88 CANADA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 148
TABLE 89 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 149
TABLE 90 EUROPE: KEY MACROINDICATORS 150
TABLE 91 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 92 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 151
TABLE 93 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 151
TABLE 94 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022–2030 (USD MILLION) 152
TABLE 95 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER,
2022–2030 (USD MILLION) 152
TABLE 96 GERMANY: KEY MACROINDICATORS 153
TABLE 97 GERMANY: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 154
TABLE 98 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 154
TABLE 99 FRANCE: KEY MACROINDICATORS 155
TABLE 100 FRANCE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 156
TABLE 101 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 156
TABLE 102 UK: KEY MACROINDICATORS 157
TABLE 103 UK: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 158
TABLE 104 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022–2030 (USD MILLION) 158
TABLE 105 ITALY: KEY MACROINDICATORS 159
TABLE 106 ITALY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 160
TABLE 107 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022–2030 (USD MILLION) 160
TABLE 108 SPAIN: KEY MACROINDICATORS 161
TABLE 109 SPAIN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 161
TABLE 110 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022–2030 (USD MILLION) 162
TABLE 111 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 163
TABLE 112 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 163
TABLE 113 ASIA PACIFIC: MACROECONOMIC INDICATORS 164
TABLE 114 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 166
TABLE 115 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 166
TABLE 116 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 167
TABLE 117 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022–2030 (USD MILLION) 168
TABLE 118 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER,
2022–2030 (USD MILLION) 168
TABLE 119 CHINA: KEY MACROINDICATORS 169
TABLE 120 CHINA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 169
TABLE 121 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022–2030 (USD MILLION) 170
TABLE 122 JAPAN: KEY MACROINDICATORS 171
TABLE 123 JAPAN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 171
TABLE 124 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022–2030 (USD MILLION) 172
TABLE 125 INDIA: KEY MACROINDICATORS 173
TABLE 126 INDIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 173
TABLE 127 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022–2030 (USD MILLION) 174
TABLE 128 AUSTRALIA: KEY MACROINDICATORS 174
TABLE 129 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 175
TABLE 130 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 175
TABLE 131 SOUTH KOREA: KEY MACROINDICATORS 176
TABLE 132 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 177
TABLE 133 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 177
TABLE 134 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 178
TABLE 135 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 178
TABLE 136 LATIN AMERICA: KEY MACROINDICATORS 179
TABLE 137 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY,
2022–2030 (USD MILLION) 180
TABLE 138 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 180
TABLE 139 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 181
TABLE 140 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022–2030 (USD MILLION) 182
TABLE 141 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER,
2022–2030 (USD MILLION) 183
TABLE 142 BRAZIL: KEY MACROINDICATORS 183
TABLE 143 BRAZIL: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 184
TABLE 144 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 185
TABLE 145 MEXICO: KEY MACROINDICATORS 186
TABLE 146 MEXICO: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 186
TABLE 147 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 187
TABLE 148 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 187
TABLE 149 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 188
TABLE 150 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY REGION,
2022–2030 (USD MILLION) 189
TABLE 151 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 189
TABLE 152 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 190
TABLE 153 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 190
TABLE 154 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION,
2022–2030 (USD MILLION) 191
TABLE 155 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER,
2022–2030 (USD MILLION) 191
TABLE 156 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY PRODUCT,
2022–2030 (USD MILLION) 192
TABLE 157 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY TECHNIQUE,
2022–2030 (USD MILLION) 193
TABLE 158 REST OF MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022–2030 (USD MILLION) 194
TABLE 159 REST OF MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022–2030 (USD MILLION) 194
TABLE 160 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET 195
TABLE 161 PCR TECHNOLOGIES MARKET: DEGREE OF COMPETITION 200
TABLE 162 PCR TECHNOLOGIES MARKET: PRODUCT FOOTPRINT 204
TABLE 163 PCR TECHNOLOGIES MARKET: APPLICATION FOOTPRINT 204
TABLE 164 PCR TECHNOLOGIES MARKET: TECHNIQUE FOOTPRINT 205
TABLE 165 PCR TECHNOLOGIES MARKET: END-USER FOOTPRINT 206
TABLE 166 PCR TECHNOLOGIES MARKET: REGION FOOTPRINT 207
TABLE 167 PCR TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 209
TABLE 168 PCR TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 210
TABLE 169 PCR TECHNOLOGIES MARKET: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–AUGUST 2024 213
TABLE 170 PCR TECHNOLOGIES MARKET: DEALS, JANUARY 2021–AUGUST 2024 213
TABLE 171 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 215
TABLE 172 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 216
TABLE 173 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–AUGUST 2024 218
TABLE 174 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–AUGUST 2024 219
TABLE 175 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 221
TABLE 176 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 222
TABLE 177 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2021–AUGUST 2024 224
TABLE 178 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–AUGUST 2024 225
TABLE 179 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 226
TABLE 180 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 227
TABLE 181 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES,
JANUARY 2021–AUGUST 2024 230
TABLE 182 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–AUGUST 2024 230
TABLE 183 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 232
TABLE 184 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 233
TABLE 185 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES,
JANUARY 2021–AUGUST 2024 236
TABLE 186 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021–AUGUST 2024 236
TABLE 187 QIAGEN: COMPANY OVERVIEW 238
TABLE 188 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 239
TABLE 189 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–AUGUST 2024 241
TABLE 190 QIAGEN: DEALS, JANUARY 2021–AUGUST 2024 242
TABLE 191 DANAHER CORPORATION: COMPANY OVERVIEW 244
TABLE 192 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 245
TABLE 193 DANAHER CORPORATION: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024 247
TABLE 194 DANAHER CORPORATION: DEALS, JANUARY 2021– AUGUST 2024 247
TABLE 195 ABBOTT: COMPANY OVERVIEW 248
TABLE 196 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED 249
TABLE 197 ABBOTT: PRODUCT APPROVALS, JANUARY 2021–AUGUST 2024 250
TABLE 198 TAKARA BIO INC.: COMPANY OVERVIEW 251
TABLE 199 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 252
TABLE 200 TAKARA BIO INC.: DEALS, JANUARY 2021– AUGUST 2024 254
TABLE 201 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW 255
TABLE 202 ANALYTIK JENA GMBH+CO. KG: PRODUCTS/SERVICES/SOLUTIONS OFFERED 255
TABLE 203 ANALYTIK JENA GMBH+CO. KG: PRODUCT LAUNCHES,
JANUARY 2021– AUGUST 2024 256
TABLE 204 ANALYTIK JENA GMBH+CO. KG: DEALS, JANUARY 2021– AUGUST 2024 257
TABLE 205 MERCK KGAA: COMPANY OVERVIEW 258
TABLE 206 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 259
TABLE 207 BIONEER CORPORATION: COMPANY OVERVIEW 263
TABLE 208 BIONEER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 264
TABLE 209 PERKINELMER: COMPANY OVERVIEW 266
TABLE 210 PERKINELMER: PRODUCTS/SERVICES/SOLUTIONS OFFERED 267
TABLE 211 PERKINELMER: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2024 268
TABLE 212 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 269
TABLE 213 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED 270
TABLE 214 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–AUGUST 2024 271
TABLE 215 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021–AUGUST 2024 272
TABLE 216 STANDARD BIOTOOLS: COMPANY OVERVIEW 273
TABLE 217 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 274
TABLE 218 HOLOGIC, INC.: COMPANY OVERVIEW 276
TABLE 219 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 277
TABLE 220 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021–AUGUST 2024 278
TABLE 221 LONZA: COMPANY OVERVIEW 279
TABLE 222 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED 280
TABLE 223 ILLUMINA, INC.: COMPANY OVERVIEW 281
TABLE 224 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 282
TABLE 225 SANSURE BIOTECH INC.: COMPANY OVERVIEW 283
TABLE 226 SANSURE BIOTECH INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 284
TABLE 227 PROMEGA CORPORATION: COMPANY OVERVIEW 285
TABLE 228 LIMINGBIO: COMPANY OVERVIEW 286
TABLE 229 EPPENDORF SE: COMPANY OVERVIEW 287
TABLE 230 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW 288
TABLE 231 DAAN GENE CO., LTD.: COMPANY OVERVIEW 289
TABLE 232 BIOBASE GROUP: COMPANY OVERVIEW 290
TABLE 233 NIPPON GENETICS EUROPE: COMPANY OVERVIEW 291
TABLE 234 BIOMÉRIEUX: COMPANY OVERVIEW 292
TABLE 235 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW 293
TABLE 236 STILLA: COMPANY OVERVIEW 294
TABLE 237 GENSCRIPT: COMPANY OVERVIEW 295
LIST OF FIGURES
FIGURE 1 PCR TECHNOLOGIES MARKET: SEGMENTS CONSIDERED 28
FIGURE 2 PCR TECHNOLOGIES MARKET: YEARS CONSIDERED 29
FIGURE 3 PCR TECHNOLOGIES MARKET: RESEARCH DATA 31
FIGURE 4 PCR TECHNOLOGIES MARKET: RESEARCH DESIGN 32
FIGURE 5 PCR TECHNOLOGIES MARKET: KEY DATA FROM SECONDARY SOURCES 34
FIGURE 6 PCR TECHNOLOGIES MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES) 35
FIGURE 7 PCR TECHNOLOGIES MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 36
FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 36
FIGURE 9 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION 37
FIGURE 10 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 38
FIGURE 11 PCR TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION 39
FIGURE 12 PCR TECHNOLOGIES MARKET: BOTTOM-UP APPROACH 40
FIGURE 13 PCR TECHNOLOGIES MARKET: TOP-DOWN APPROACH 40
FIGURE 14 DATA TRIANGULATION METHODOLOGY 42
FIGURE 15 GROWTH PROJECTIONS ON REVENUE IMPACT OF KEY MACROINDICATORS 44
FIGURE 16 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024 VS. 2030 (USD MILLION) 46
FIGURE 17 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024 VS. 2030 (USD MILLION) 47
FIGURE 18 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION) 48
FIGURE 19 PCR TECHNOLOGIES MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 49
FIGURE 20 PCR TECHNOLOGIES MARKET: REGIONAL SNAPSHOT 50
FIGURE 21 INCREASING DEMAND FOR ADVANCED PCR TECHNOLOGIES TO DRIVE MARKET 51
FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD 52
FIGURE 23 US AND DIAGNOSTIC LABORATORIES COMMANDED LARGEST MARKET SHARE
IN 2023 53
FIGURE 24 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030 54
FIGURE 25 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
FIGURE 26 PCR TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS 64
FIGURE 27 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 65
FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 67
FIGURE 29 KEY BUYING CRITERIA FOR TOP FOUR END USERS 68
FIGURE 30 PATENT ANALYSIS FOR PCR TECHNOLOGIES (JANUARY 2014–AUGUST 2024) 68
FIGURE 31 AVERAGE SELLING PRICE TREND OF PCR TECHNOLOGY EQUIPMENT, BY REGION, 2021–2023 (USD) 75
FIGURE 32 AVERAGE SELLING PRICE OF PCR INSTRUMENTS, BY KEY PLAYER, 2023 (USD) 76
FIGURE 33 PCR TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS 78
FIGURE 34 PCR TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS 80
FIGURE 35 PCR TECHNOLOGIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
FIGURE 36 INVESTMENT AND FUNDING SCENARIO, 2019–2023 89
FIGURE 37 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 90
FIGURE 38 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION) 90
FIGURE 39 PCR TECHNOLOGIES MARKET: IMPACT OF AI/GEN AI 92
FIGURE 40 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT 141
FIGURE 41 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT 165
FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN PCR TECHNOLOGIES MARKET
(2019–2023) 197
FIGURE 43 PCR INSTRUMENTS MARKET SHARE ANALYSIS (2023) 198
FIGURE 44 PCR REAGENTS AND CONSUMABLES MARKET SHARE ANALYSIS (2023) 198
FIGURE 45 PCR SOFTWARE AND SERVICES MARKET SHARE ANALYSIS (2023) 199
FIGURE 46 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 202
FIGURE 47 PCR TECHNOLOGIES MARKET: COMPANY FOOTPRINT 203
FIGURE 48 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 208
FIGURE 49 EV/EBITDA OF KEY VENDORS 210
FIGURE 50 5-YEAR STOCK BETA OF KEY VENDORS 211
FIGURE 51 PCR TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 212
FIGURE 52 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 216
FIGURE 53 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 222
FIGURE 54 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 227
FIGURE 55 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 233
FIGURE 56 QIAGEN: COMPANY SNAPSHOT 239
FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT 245
FIGURE 58 ABBOTT: COMPANY SNAPSHOT 249
FIGURE 59 TAKARA BIO INC.: COMPANY SNAPSHOT 252
FIGURE 60 MERCK KGAA: COMPANY SNAPSHOT 259
FIGURE 61 BIONEER CORPORATION: COMPANY SNAPSHOT 263
FIGURE 62 PERKINELMER: COMPANY SNAPSHOT 267
FIGURE 63 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 270
FIGURE 64 STANDARD BIOTOOLS: COMPANY SNAPSHOT 274
FIGURE 65 HOLOGIC, INC.: COMPANY SNAPSHOT 277
FIGURE 66 LONZA: COMPANY SNAPSHOT 280
FIGURE 67 ILLUMINA, INC.: COMPANY SNAPSHOT 282
FIGURE 68 SANSURE BIOTECH INC.: COMPANY SNAPSHOT 283
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後2営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
割引可能なレポートが多数ございます。価格・サンプルについてはお気軽にご相談ください。
最新調査レポート
- 沈降シリカ市場 – 2030年までの世界予測 2025-03-07
- スマートメーター市場 – 2030年までの世界予測 2025-03-07
- 産業用計測市場 – 2030年までの世界予測 2025-03-06
- 精密ろ過膜市場- 2029年までの世界予測 2025-03-06
- グリーンテクノロジーと持続可能性市場 – 2030年までの世界予測 2025-03-06